输卵管异位妊娠的治疗管理:CNGOF与SCGP临床实践指南
该指南由CNGOF与SCGP制定,针对输卵管异位妊娠的治疗管理提出推荐。输卵管异位妊娠占异位妊娠的96%至99%,管理应依据其活性及有无症状。有症状或活性输卵管异位妊娠不推荐期待治疗(强推荐,低质量证据);非活性无症状者,期待治疗可作为MTX治疗或手术治疗的替代方案(强推荐,低至极低质量证据)。期待治疗需在48小时临床和生物学再评估,hCG下降>15%则每周监测至阴性;hCG上升>15%或出现症状则停止期待治疗。药物治疗推荐单剂量MTX方案优于多剂量方案以减少不良反应,不推荐常规联合米非司酮。手术推荐根据生育情况行输卵管切开术或切除术,不推荐输卵管挤压术。
要点
- 有症状或活性输卵管异位妊娠不推荐期待治疗(强推荐,低质量证据)。
- 非活性无症状输卵管异位妊娠,期待治疗可作为MTX治疗或手术治疗的替代方案(强推荐)。
- 期待治疗者48小时需临床和生物学再评估;hCG下降>15%则每周监测至阴性。
- 期待治疗中hCG上升>15%或出现症状,应停止期待治疗(强推荐,低质量证据)。
- 药物治疗推荐单剂量MTX方案优于多剂量方案以减少不良反应(强推荐,高质量证据)。
适用人群与场景
- 输卵管异位妊娠患者,定义为妊娠或妊娠残留物位于输卵管肌层外部分(峡部、壶腹部或伞部)。
- 管理应依据异位妊娠的活性及有无症状。
诊断标准与关键阈值
- 期待治疗中hCG下降>15%(48小时):继续每周监测直至阴性。
- 期待治疗中hCG上升>15%(48小时)或出现症状:停止期待治疗。
处置流程与药物剂量
- 有症状的输卵管异位妊娠:不推荐期待治疗(强推荐,低质量证据)。
- 活性输卵管异位妊娠:不推荐期待治疗(强推荐,低质量证据)。
- 非活性且无症状的输卵管异位妊娠:期待治疗可作为MTX治疗的替代方案(强推荐,低质量证据)。
- 非活性且无症状的输卵管异位妊娠:期待治疗可作为手术治疗的替代方案(强推荐,极低质量证据)。
- 期待治疗者:48小时系统进行临床和生物学再评估(强推荐,低质量证据)。
- 期待治疗中48小时hCG下降>15%且无输卵管异位妊娠症状:继续每周监测直至hCG阴性(强推荐,极低质量证据)。
- 期待治疗中48小时hCG上升>15%或出现输卵管异位妊娠症状:停止期待治疗(强推荐,低质量证据)。
- 药物治疗:不推荐多剂量MTX方案优于单剂量方案以提高成功率(强推荐,中等质量证据);推荐单剂量MTX方案优于多剂量方案以限制不良反应风险(强推荐,高质量证据);不推荐常规联合米非司酮与MTX注射以提高疗效(强推荐,高质量证据)。
红旗征与不能漏的情况
- 症状性输卵管异位妊娠:不推荐期待治疗(强推荐,低质量证据)。
- 活性输卵管异位妊娠:不推荐期待治疗(强推荐,低质量证据)。
- 期待治疗中hCG上升>15%或出现症状:停止期待治疗(强推荐,低质量证据)。
研究设计与关键结果
- 制定机构:CNGOF与SCGP;方法:临床实践指南;证据分级体系:原文使用强推荐及证据质量(低、极低、中等、高)分级。
证据类型、等级与局限
- 证据类型:临床实践指南;推荐强度与证据质量照录原文(强推荐,低质量证据;强推荐,极低质量证据;强推荐,中等质量证据;强推荐,高质量证据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 有症状或活性输卵管异位妊娠不应考虑期待治疗,应转向药物或手术管理(强推荐,低质量证据)。
- 非活性无症状输卵管异位妊娠可与患者讨论期待治疗作为MTX或手术的替代方案(强推荐,低质量证据至极低质量证据)。
- 选择期待治疗时,必须在48小时进行临床和生物学再评估,并根据hCG变化(下降>15%继续每周监测至阴性;上升>15%或出现症状停止期待治疗)决策。
- MTX治疗首选单剂量方案而非多剂量方案以减少不良反应(强推荐,高质量证据),不常规联合米非司酮(强推荐,高质量证据)。
- 手术治疗根据生育情况行输卵管切开术或输卵管切除术(强推荐,高质量证据),不推荐输卵管挤压术以降低发病率(强推荐,极低质量证据)。
指南或共识出处
- 指南名称:输卵管异位妊娠的治疗管理:CNGOF与SCGP临床实践指南;发布机构:CNGOF与SCGP;年份:原文未提及。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Ectopic Pregnancy is defined as the presence of a pregnancy or pregnancy residue outside the uterine cavity, with a prevalence of approximately 2%. Tubal ectopic pregnancy is defined as the presence of a pregnancy or pregnancy residue in the extra-myometrial portion of the fallopian tube (isthmus, ampulla, or fimbriae), and accounts for 96 to 99% of ectopic pregnancy locations. Management of tubal ectopic pregnancy should depend on both its activity and whether it is symptomatic or not. Regarding emergency management of tubal ectopic pregnancy, it is recommended not to consider expectant management for patients with symptomatic tubal ectopic pregnancy, nor for patients with active tubal ectopic pregnancy (Strong recommendation, low quality of evidence). It is recommended to offer expectant management as an alternative to medical treatment with MTX (methotrexate) for patients with non-active and asymptomatic tubal ectopic pregnancy (Strong recommendation, low quality of evidence). It is recommended to offer expectant management as an alternative to surgical treatment for patients with non-active and asymptomatic tubal ectopic pregnancy (Strong recommendation, very low quality of evidence). In cases of expectant management of tubal ectopic pregnancy, it is strongly recommended to systematically re-evaluate the patient clinically and biologically at 48hours (Strong recommendation, low quality of evidence). If hCG levels decrease by more than 15% at 48hours, it is recommended to continue monitoring weekly until negativity, provided there are no signs of symptomatic tubal ectopic pregnancy (Strong recommendation, very low quality of evidence). If an expectant approach is chosen, and there is an increase in hCG levels of more than 15% at 48hours or the tubal ectopic pregnancy becomes symptomatic, it is recommended to discontinue expectant management (Strong recommendation, low quality of evidence). Regarding medical treatment of tubal ectopic pregnancy, it is recommended not to favor a multi-dose protocol over a single-dose protocol to increase the success rate of MTX treatment (Strong recommendation, moderate quality of evidence). It is recommended to prefer the single-dose MTX protocol over the multi-dose protocol to limit the risk of adverse effects (Strong recommendation, high quality of evidence). It is also recommended not to systematically combine mifepristone treatment with an MTX injection to improve the efficacy of medical treatment for tubal ectopic pregnancy (Strong recommendation, high quality of evidence). Regarding surgical management, in a patient with tubal ectopic pregnancy, it is recommended to perform either salpingotomy or salpingectomy with regard to fertility (Strong recommendation, high quality of evidence). It is recommended not to perform tubal expression in order to reduce morbidity compared to salpingotomy (Strong recommendation, very low quality of evidence).
参考来源
- Agostini A, Legendre G, Margueritte F, et al. [Therapeutic management of tubal ectopic pregnancies: Clinical practice guidelines of CNGOF and SCGP]. Gynecol Obstet Fertil Senol. 2025. PMID: 41183782. doi:10.1016/j.gofs.2025.10.023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。